Anuh Pharma Ltd Technical Momentum Shifts Amid Bearish Signals

Technical Trend Overview and Price Movement

As of 2 March 2026, Anuh Pharma’s share price closed at ₹77.00, down 1.09% from the previous close of ₹77.85. The stock traded within a range of ₹76.56 to ₹78.68 during the day, remaining closer to its 52-week low of ₹68.00 than its high of ₹115.00. This price action reflects a cautious market sentiment amid a broader bearish technical trend.

The technical trend has shifted from mildly bearish to outright bearish, signalling increased selling pressure. Daily moving averages are firmly bearish, indicating that short-term momentum is weakening. The weekly MACD remains mildly bullish, suggesting some underlying strength, but this is counterbalanced by a bearish monthly MACD, which points to longer-term downtrends.

Momentum Indicators: MACD, RSI, and KST

The Moving Average Convergence Divergence (MACD) indicator presents a mixed picture. On a weekly basis, it is mildly bullish, implying some short-term upward momentum. However, the monthly MACD is bearish, signalling that the longer-term trend remains negative. This divergence between weekly and monthly MACD readings suggests that while short-term rallies may occur, the dominant trend is still downward.

The Relative Strength Index (RSI) on both weekly and monthly charts currently shows no clear signal, hovering in neutral territory. This lack of momentum in RSI indicates that the stock is neither overbought nor oversold, which could mean a period of consolidation or indecision among traders.

The Know Sure Thing (KST) indicator aligns with the MACD’s mixed signals: mildly bullish on the weekly timeframe but bearish monthly. This further reinforces the notion that short-term momentum may be improving slightly, but the broader trend remains under pressure.

Bollinger Bands and On-Balance Volume (OBV) Analysis

Bollinger Bands on both weekly and monthly charts are mildly bearish, indicating that price volatility is skewed towards the downside. The stock price is closer to the lower band, which often acts as a support level but also signals potential weakness if breached decisively.

On-Balance Volume (OBV) readings are mildly bearish on both weekly and monthly scales, suggesting that volume trends are not supporting a strong price rally. This volume weakness could imply that recent price declines are backed by genuine selling rather than low-volume fluctuations.

Moving Averages and Dow Theory Signals

Daily moving averages are bearish, reinforcing the short-term downtrend. This suggests that the stock’s recent price action is below its key average price levels, which often acts as resistance in a declining market.

Dow Theory assessments show a mildly bearish weekly trend, while the monthly trend is classified as having no clear direction. This indicates that while short-term price action is negative, the longer-term trend remains uncertain, potentially awaiting a decisive breakout or breakdown.

Comparative Performance: Anuh Pharma vs Sensex

When analysing returns relative to the benchmark Sensex, Anuh Pharma has delivered mixed results. Over the past week, the stock gained 2.52%, outperforming the Sensex’s decline of 1.84%. Over one month, the stock’s return of 7.75% also surpassed the Sensex’s negative 0.70%. However, year-to-date (YTD) returns show a decline of 4.32%, slightly better than the Sensex’s 4.62% fall.

Over longer horizons, the stock’s performance is more nuanced. The one-year return is negative at -3.48%, contrasting with the Sensex’s robust 8.95% gain. Over three years, Anuh Pharma has significantly outperformed the Sensex with an 83.55% return versus 37.10%. Yet, over five and ten years, the stock’s returns of 37.75% and 34.15% lag behind the Sensex’s 65.55% and 251.07%, respectively.

This mixed performance highlights the stock’s volatility and sector-specific challenges, despite some periods of strong outperformance.

Mojo Score and Ratings Update

Anuh Pharma’s current Mojo Score stands at 34.0, with a Mojo Grade of Sell, upgraded from a previous Strong Sell rating on 4 February 2026. This slight improvement reflects some stabilisation in technical parameters but remains firmly negative overall. The Market Cap Grade is 4, indicating a mid-tier market capitalisation relative to peers.

The downgrade in technical trend to bearish and the mixed signals from momentum indicators suggest that investors should exercise caution. The stock’s technical profile does not currently support a strong buy stance, and the Sell rating aligns with the prevailing downward momentum.

Investor Takeaway and Outlook

Technical analysis of Anuh Pharma Ltd reveals a stock grappling with bearish momentum despite intermittent short-term bullish signals. The divergence between weekly and monthly indicators such as MACD and KST suggests that while some short-term rallies may occur, the dominant trend remains downward.

Investors should note the bearish daily moving averages and the mildly bearish Bollinger Bands and OBV readings, which collectively point to sustained selling pressure. The neutral RSI readings imply a lack of strong momentum either way, indicating potential consolidation or sideways movement in the near term.

Comparatively, Anuh Pharma’s recent outperformance against the Sensex in the short term is encouraging but tempered by weaker longer-term returns and a cautious technical outlook. The upgrade from Strong Sell to Sell rating by MarketsMOJO reflects this nuanced view, signalling that while the worst may be behind, significant upside remains uncertain.

Given the current technical landscape, investors may prefer to monitor the stock for a confirmed trend reversal or stronger bullish signals before increasing exposure. Meanwhile, exploring alternative stocks with more robust momentum and technical strength could be a prudent strategy.

Only Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Start Today